Streetbeat News

Analyst Ratings

AMAM

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Ambrx Biopharma (NASDAQ:AMAM) and maintained a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:29 pm

ALNY

Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a $190 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:27 pm

SEDG

B of A Securities analyst Julien Dumoulin-Smith has downgraded SolarEdge Technologies (NASDAQ:SEDG) from Buy to Neutral and lowered the price target from $320 to $181.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:25 pm

SNPS

Synopsys, Inc. (NASDAQ:SNPS) is set to report its Q3 2023 financial results on Aug. 16, 2023. Analysts predict earnings of $2.74 per share, up from $2.1 per share a year ago, and revenue of $1.48 billion, up from $1.25 billion. The company's shares closed at $436.74 on Tuesday. Recent analyst ratings include Wells Fargo's Overweight rating with a price target of $505, Baird's Outperform rating with a price target of $447, B of A Securities' upgrade to Buy with a price target of $410, and Stifel's initiation of coverage with a Buy rating and a price target of $445.

Portfolio Pulse from Lisa Levin

August 16, 2023 | 1:23 pm

SNDX

JP Morgan analyst Anupam Rama has maintained an Overweight rating on Syndax Pharmaceuticals (NASDAQ:SNDX) but lowered the price target from $36 to $33.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:22 pm

RAPT

JP Morgan analyst Anupam Rama has maintained an Overweight rating on RAPT Therapeutics (NASDAQ:RAPT) but lowered the price target from $39 to $32.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:17 pm

MRCY

JP Morgan analyst Seth Seifman maintains a Neutral rating on Mercury Systems (NASDAQ:MRCY) and lowers the price target from $37 to $35.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:16 pm

AZN

MRNA

NVO

Chinese pharmaceutical companies are developing local versions of advanced weight-loss medications, aiming to compete with Novo Nordisk A/S. The new drugs could offer more affordable alternatives in Western markets. Western pharmaceutical companies, including Moderna Inc and AstraZeneca plc, are expanding their presence in China to leverage opportunities from the aging population. Novo Nordisk's Wegovy is expected to receive Chinese approval soon.

Portfolio Pulse from Vandana Singh

August 16, 2023 | 1:15 pm

BHVN

JP Morgan analyst Tessa Romero maintains an Overweight rating on Biohaven (NYSE:BHVN) but has lowered the price target from $27 to $24.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:15 pm

A

JP Morgan analyst Tycho Peterson has maintained an Overweight rating on Agilent Technologies (NYSE:A) but lowered the price target from $155 to $150.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:14 pm